The treatment being studied involves the use of fludarabine phosphate, which is administered through an intravenous line, meaning it is delivered directly into a vein. This medication is used alongside cyclophosphamide as part of the preparation process. The study also takes into account patients who have previously received or are scheduled to receive other specialized cell therapies, such as tisagenlecleucel, axicabtagene ciloleucel, brexucabtagene autoleucel, or ciltacabtagene autoleucel. The goal is to understand the pharmacokinetics, or how the drug moves through, is absorbed by, and is eliminated from the body.

During the course of the study, blood samples will be collected to measure the levels of the medication in the blood over time. These measurements help determine the maximum observed concentration and the overall exposure to the drug. Researchers will also look at various patient factors, such as weight and kidney function, to see how they might relate to how the body handles the medication.

The main purpose of this research is to understand how safe the medication is and how well patients can tolerate it. The study will evaluate AZD2962 both when given alone and when combined with other treatments. Researchers will also determine the most effective dose of the medication that can be safely given to patients.

During the study, participants will take the medication and undergo regular check-ups to monitor their health. Doctors will track how patients respond to the treatment by examining their blood and bone marrow samples. The study will also measure how long the medication stays in the body and how it affects the blood disorder over time.

The study involves patients who have blood cancers and require a stem cell transplant from a family member who is a partial match (haploidentical donor). All participants will receive a thiotepa-based conditioning regimen (preparatory treatment) before the transplant. After the transplant, patients will be randomly assigned to receive either the standard or reduced dose of cyclophosphamide, which helps prevent rejection of the donor cells and reduces the risk of graft-versus-host disease (a condition where donor cells attack the recipient’s body).

Participants will be monitored for two years after transplantation to assess survival, cancer relapse, treatment side effects, and quality of life. The researchers will evaluate whether the reduced dose of cyclophosphamide provides similar benefits to the standard dose while potentially causing fewer complications.

The purpose of the study is to determine if the high-dose vaccine leads to a better immune response compared to the standard-dose vaccine. Participants will receive one of the two vaccines, and their immune response will be monitored over time. The study will also include a group of healthy individuals to compare how their immune systems respond to the vaccine. The main goal is to see if the high-dose vaccine can increase the rate of seroconversion, which means developing antibodies against the flu virus, in patients with hematological cancer.

Throughout the study, researchers will also look at how the immune system is activated in response to the vaccines and try to identify any factors that might predict a better response to the vaccine. This information could help improve flu vaccination strategies for patients with hematological cancers in the future. Participants will be monitored for any side effects or adverse events following vaccination to ensure their safety.

The purpose of the study is to see if FMT can help prevent complications after the stem cell transplant. Specifically, the study aims to improve the chances of patients staying free from a condition called graft-versus-host disease (GVHD) and cancer relapse for one year after their transplant. GVHD is a condition where the donor’s immune cells attack the patient’s body. The study will compare the effects of FMT with no additional treatment to see if it makes a difference in patient outcomes.

Participants in the study will receive the FMT treatment and be monitored over time to assess their health and any side effects. The study will look at various factors, including overall survival, the occurrence of infections, and the quality of life of the patients. The goal is to determine if FMT can be a safe and effective way to support patients after their stem cell transplant and improve their long-term health.

The purpose of the study is to evaluate the safety and effectiveness of SMART101 in patients who have received a stem cell transplant from a donor whose tissue type does not completely match their own. The study will be conducted in two segments. In the first segment, researchers will determine the best dose of SMART101 to use. In the second segment, they will assess how safe the treatment is and how well it works in helping the immune system recover, particularly focusing on the reconstitution of CD4+ T-cells, which are important for fighting infections.

Participants in the study will receive the SMART101 treatment after their stem cell transplant, along with a medication called cyclophosphamide, which is used to help prevent complications. The study will monitor participants for any unexpected side effects and measure how well their immune system recovers over time. The goal is to find out if SMART101 can make stem cell transplants safer and more effective for patients with blood cancers.

The treatment being studied is called CLOTTAFACT, which contains human fibrinogen and is given through an intravenous injection. The purpose of the study is to see if adding fibrinogen to platelet transfusions can improve blood clotting in patients whose bodies don’t respond well to platelet transfusions alone. The study will measure how well the blood clots before and after receiving the combined treatment.

During the study, patients will receive fibrinogen followed by a platelet transfusion. Blood samples will be taken at different times to measure how well the treatment works. The study will also track any bleeding events or other health issues that occur during the treatment period. The amount of fibrinogen given will be based on the patient’s body weight, with a maximum single dose of 1.5 grams.

The study is divided into two parts. In the first part, patients with various types of advanced solid tumors or blood cancers will receive ICT01 either alone or together with pembrolizumab. The second part will explore the effects of ICT01 in combination with pembrolizumab for solid tumors and with other medications like venetoclax (known as Venclyxto or Venclexta) and azacitidine (known as Vidaza) for patients newly diagnosed with acute myeloid leukemia (AML).

Throughout the study, patients will receive the treatments through an intravenous infusion, which means the medication is given directly into a vein. The trial will monitor the patients for any side effects and assess how the cancer responds to the treatment. The goal is to gather information that could lead to new treatment options for people with these challenging types of cancer.

The purpose of this study is to evaluate the safety and tolerability of GEN3014 and to determine the appropriate dose for future studies. Participants will receive either GEN3014 or DARZALEX, and some may receive a placebo. The study will monitor participants for any side effects and how well the treatment is tolerated. The trial will also assess how the body processes GEN3014 and its effects on the disease.

Participants will be involved in the study for a period of time, during which they will receive regular check-ups and monitoring. The study aims to gather information that could help improve treatment options for people with these types of cancers. The trial is expected to continue until 2026, with the goal of finding effective and safe treatment options for patients with relapsed or refractory multiple myeloma and other hematologic malignancies.

The purpose of the study is to determine the 1-year survival rate of patients treated with 9-ING-41 compared to those who do not receive this treatment. The study will explore how well the drug works when used alone or in combination with other chemotherapy drugs. Patients will receive the treatment through intravenous administration, which means the drug is delivered directly into the bloodstream through a vein. The study will monitor patients over time to see how their cancer responds to the treatment and to check for any side effects.

Throughout the study, researchers will collect information on various outcomes, such as how long patients live without their cancer getting worse, the overall survival time, and any changes in the size of the tumors. The study will also look at the disease control rate, which includes patients whose cancer remains stable or shows improvement. By participating in this study, researchers hope to gather valuable data that could lead to new treatment options for patients with these challenging types of cancer.

The purpose of this study is to evaluate the long-term safety of these investigational drugs in patients with advanced cancers. Participants in this study are those who are already part of a related study and continue to benefit from the treatment. The study will monitor the safety of the treatments by observing any side effects, especially those that are serious or affect vital organs like the heart, liver, or brain. The study will also look at overall survival, which is the time from the start of treatment until death from any cause.

During the study, participants will receive the investigational drugs over a period, with the maximum treatment period for some drugs being up to 178 days. The study aims to ensure that the treatments are safe for long-term use and to gather more information on their effects. Participants will be closely monitored throughout the study to ensure their safety and well-being.

The purpose of this study is to evaluate the safety and effectiveness of zilovertamab vedotin in treating these cancers. The study is divided into two parts. In the first part, the focus is on understanding how safe the treatment is and how well it is tolerated by participants aged 1 to under 18 years. The second part looks at the treatment’s ability to reduce or eliminate the cancer in participants from birth to 25 years old. The study will monitor participants for any side effects and how their cancer responds to the treatment.

Participants in the study will receive either the treatment or a placebo. The study will track various outcomes, such as the number of participants who experience side effects, the number who need to stop the treatment due to side effects, and the number who need to change their dose. The study will also look at how the treatment affects the cancer, including whether it helps reduce the size of the tumors or leads to remission. The study is expected to continue until 2029, providing valuable information on the potential benefits and risks of using zilovertamab vedotin for these types of cancers in young patients.

Participants in the study will receive the treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will be conducted in two parts. In the first part, researchers will focus on understanding the safety and how the body processes the investigational agents. In the second part, the study will continue to evaluate the safety and also look at how effective the treatment is in shrinking or controlling the cancer. The study will monitor participants for any side effects and measure how the cancer responds to the treatment.

The goal of this study is to gather information that could lead to new treatment options for young patients with these types of cancers. The study will run until 2029, allowing researchers to collect comprehensive data on the long-term effects and benefits of the treatment. This research is important for developing new therapies that could improve outcomes for children and young adults facing these challenging diseases.

The purpose of the study is to determine how safe and tolerable Karonudib is when given in increasing doses to patients with advanced stages of these blood cancers, especially those who have not responded to previous treatments or whose disease has returned. Additionally, the study will explore the safety and tolerability of Karonudib when used in combination with other cancer-fighting drugs for patients with advanced, relapsed, or refractory AML and high-risk MDS.

Participants in the study will receive Karonudib orally, and the study will monitor their response to the treatment over time. The trial aims to gather information on how patients tolerate the medication and any side effects they may experience. The study is expected to continue until early 2026, providing valuable insights into the potential benefits and risks of Karonudib for treating these serious blood cancers.

The purpose of this study is to monitor the safety of this treatment over an extended period. Participants in the study have already received the CRISPR CAR cellular therapy. The study will track any side effects or adverse events that may occur, including serious ones, to ensure the treatment is safe for long-term use. Additionally, the study will look at how long participants survive and how long they remain in remission, which means the cancer is not active or growing.

Throughout the study, participants will be regularly monitored by healthcare professionals. This will involve routine check-ups and assessments to gather information about their health and any changes they experience. The study aims to provide valuable insights into the long-term effects of CRISPR CAR cellular therapy, contributing to the understanding and development of new cancer treatments.

The purpose of the study is to evaluate how effective this low-dose treatment is in preventing GVH in older patients who have received this type of transplant. The study will follow patients over a period of time to monitor their health and any side effects they may experience. Patients will receive the treatment through an infusion, which means the medication is given directly into the bloodstream. The study will track the occurrence of GVH and other health outcomes at various points in time after the transplant, such as 30, 60, 90, and 100 days, and up to one year.

Throughout the study, researchers will also look at other important health measures, such as the number of certain immune cells in the blood, the incidence of infections, and overall survival rates. The quality of life of participants will be assessed using a questionnaire designed for patients who have undergone bone marrow transplants. This study aims to provide valuable information on how to better protect patients from GVH and improve their overall outcomes after a stem cell transplant.

Participants in the study will take the medications orally, meaning they will swallow them in the form of tablets. The study will begin with a phase where the dose of CA-4948 is gradually increased to find the safest and most effective dose. After this phase, the study will expand to include more patients to further assess the treatment’s safety and how well it works. Throughout the study, doctors will monitor participants closely for any side effects and changes in their health. The study aims to provide valuable information about the potential benefits and risks of using CA-4948 in combination with Ibrutinib for treating PCNSL.

This trial is expected to continue until 2028, allowing researchers to gather comprehensive data on the treatment’s long-term effects. Participants will undergo regular health check-ups, including tests like MRI scans, to track the progress of their condition and the impact of the treatment. The study is designed to ensure that all participants receive the best possible care while contributing to important research that could improve future treatment options for PCNSL.

The purpose of this study is to evaluate the safety and effectiveness of using favezelimab in combination with pembrolizumab, as well as to assess each medication when used alone. Participants in the study will receive these treatments and will be monitored for any side effects or reactions. The study aims to determine the best dose for future research and to understand how well these treatments work together or separately in treating hematologic malignancies.

Throughout the study, participants will undergo regular check-ups and tests to monitor their health and the effects of the treatment. This includes measuring the concentration of the medications in the blood and observing any changes in the cancer. The study will help researchers gather important information about these treatments, which could lead to better options for patients with hematologic malignancies in the future.

The purpose of this study is to monitor the long-term effects of these gene-modified cell therapies. Researchers are particularly interested in understanding any late-onset side effects that might occur, such as neurological disorders, autoimmune disorders, blood-related disorders, serious infections, and the development of new cancers. The study will also look at how these treatments might affect the growth and development of children and teenagers who have received them. Participants will be followed over a long period to gather this information.

Throughout the study, participants will receive regular check-ups to assess their health and any potential side effects. This includes monitoring for any new symptoms or changes in their condition. The study aims to provide valuable insights into the safety and long-term impact of these innovative cancer treatments, helping to improve future therapies and patient care.

The purpose of this study is to provide continued treatment and monitor the safety of tafasitamab in patients who have already been receiving this medication in previous studies. Participants in this study will continue to receive tafasitamab as part of their treatment plan. The study will observe how patients respond to the medication over time and will monitor any side effects or adverse reactions that may occur. This ongoing treatment aims to support patients who have shown a positive response or stable disease condition with tafasitamab in earlier studies.

Throughout the study, patients will have regular visits to receive their treatment and to check on their health status. The study will last for a period of time, allowing researchers to gather important information about the long-term use of tafasitamab in treating hematologic cancers. This information will help in understanding the safety and effectiveness of the medication for patients who continue to benefit from it.